Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Am J Hematol

Retrieve available abstracts of 89 articles:
HTML format

Single Articles

    May 2023
  1. BENNETT R, Ruskova A, Coomarasamy C, Theakston E, et al
    Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
    Am J Hematol. 2023 May 10. doi: 10.1002/ajh.26953.
    PubMed     Abstract available

  2. HUNTINGTON SF, Schuster SJ, Ding W, Koehler AB, et al
    DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
    Am J Hematol. 2023;98:739-749.
    PubMed     Abstract available

    April 2023
  3. MICHOT JM, Quivoron C, Sarkozy C, Danu A, et al
    Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study.
    Am J Hematol. 2023;98:645-657.
    PubMed     Abstract available

    March 2023
  4. SUN P, Li Y, Li C, Ren K, et al
    A Phase II Study of Sintilimab, Anlotinib, and Pegaspargase Sandwiched with Radiotherapy as First-line Therapy in Patients with Newly Diagnosed, Stage I-II Extranodal Natural-killer/T-cell Lymphoma.
    Am J Hematol. 2023 Mar 27. doi: 10.1002/ajh.26922.
    PubMed     Abstract available

  5. DAVID KA, Sundaram S, Kim SH, Vaca R, et al
    Older Patients with Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 US Cancer Centers.
    Am J Hematol. 2023 Mar 25. doi: 10.1002/ajh.26919.
    PubMed     Abstract available

  6. GONZALEZ BARCA E, Tomas-Roca L, Esteve A, Rodriguez M, et al
    Extranodal natural killer/T-cell lymphoma nasal type in a western population: molecular profiling identifies new therapeutic targets.
    Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26904.

  7. DESIKAN SP, Senapati J, Jabbour E, Abuasab T, et al
    Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia.
    Am J Hematol. 2023 Mar 6. doi: 10.1002/ajh.26907.

    February 2023
  8. MEJIA SALDARRIAGA M, Alhomoud M, Roboz G, Allan JN, et al
    Angioimmunoblastic T-cell lymphoma presenting with severe plasmacytosis mimicking plasma cell leukemia.
    Am J Hematol. 2023 Feb 13. doi: 10.1002/ajh.26878.

  9. CASTILLO JJ, Buske C, Trotman J, Sarosiek S, et al
    Bruton tyrosine kinase inhibitors in the management of Waldenstrom macroglobulinemia.
    Am J Hematol. 2023;98:338-347.
    PubMed     Abstract available

  10. AGRAWAL V, Salhotra A, Song J, Gu Z, et al
    The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.
    Am J Hematol. 2023;98:E38-E40.

    January 2023
  11. ALDOSS I, Shah BD, Park JH, Muffly L, et al
    Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2023 Jan 24. doi: 10.1002/ajh.26853.
    PubMed     Abstract available

  12. XU W, Zhou K, Wang T, Yang S, et al
    Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study.
    Am J Hematol. 2023 Jan 22. doi: 10.1002/ajh.26826.
    PubMed     Abstract available

  13. DESAI SH, Spinner MA, David K, Bachanova V, et al
    Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Am J Hematol. 2023 Jan 11. doi: 10.1002/ajh.26827.
    PubMed     Abstract available

  14. LASATER EA, Amin DN, Bannerji R, Mali RS, et al
    Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R NHL: Results from preclinical models and a Phase Ib study.
    Am J Hematol. 2023 Jan 2. doi: 10.1002/ajh.26809.
    PubMed     Abstract available

  15. HRISTOV AC, Tejasvi T, Wilcox RA
    Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2023;98:193-209.
    PubMed     Abstract available

  16. BEATON B, Sasson SC, Rankin K, Raedemaeker J, et al
    Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti-spike neutralizing IgG to SARS-CoV-2 variants, but preserved antigen-specific T cell responses.
    Am J Hematol. 2023;98:131-139.
    PubMed     Abstract available

  17. HESS BT, Giri A, Park Y, Patel KK, et al
    Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26784.
    PubMed     Abstract available

  18. LUDVIGSEN AL-MASHHADI A, Cederleuf H, Kuhr Jensen R, Holm Nielsen T, et al
    Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
    Am J Hematol. 2023 Jan 1. doi: 10.1002/ajh.26803.
    PubMed     Abstract available

    December 2022
  19. INAMOTO Y, Takeda W, Hirakawa T, Sakaguchi H, et al
    Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis.
    Am J Hematol. 2022;97:1568-1579.
    PubMed     Abstract available

    November 2022
  20. PERRIELLO VM, Falini L, Ruggeri L, Innocente A, et al
    CAR T cell-driven cerebrospinal fluid cytokine storm with confounding neurological picture in chemorefractory primary cardiac lymphoma.
    Am J Hematol. 2022 Nov 8. doi: 10.1002/ajh.26777.

    Management of relapsed/refractory Chronic Lymphocytic Leukemia.
    Am J Hematol. 2022;97 Suppl 2:S11-S18.
    PubMed     Abstract available

    Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2022;97:1478-1488.
    PubMed     Abstract available

    October 2022
  23. ALDULESCU M, Leuer K, Jennings LJ, Yap KL, et al
    Lineage switch from acute myeloid leukemia to B-lymphoblastic lymphoma with acquired PIK3R1 loss-of-function mutation.
    Am J Hematol. 2022 Oct 26. doi: 10.1002/ajh.26770.

  24. NOWAKOWSKI G, Maurer MJ, Cerhan JR, Dey D, et al
    Utilization of Real-World Data in Assessing Treatment Effectiveness for Diffuse Large B-Cell Lymphoma.
    Am J Hematol. 2022 Oct 17. doi: 10.1002/ajh.26767.
    PubMed     Abstract available

  25. KITTAI AS, Huang Y, Beckwith KA, Bhat SA, et al
    Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib.
    Am J Hematol. 2022 Oct 10. doi: 10.1002/ajh.26755.
    PubMed     Abstract available

  26. Abstracts from the 2022 Lymphoma, Leukemia and Myeloma Congress October 18-22, 2022.
    Am J Hematol. 2022;97 Suppl 3:S3-S40.

    September 2022
  27. RADKIEWICZ C, Bruchfeld JB, Weibull CE, Jeppesen ML, et al
    Sex differences in lymphoma incidence and mortality by subtype: a population-based study.
    Am J Hematol. 2022 Sep 30. doi: 10.1002/ajh.26744.
    PubMed     Abstract available

    Follicular lymphoma: 2023 update on diagnosis and management.
    Am J Hematol. 2022 Sep 17. doi: 10.1002/ajh.26737.
    PubMed     Abstract available

  29. LACKRAJ T, Barouch SB, Medeiros JJF, Pedersen S, et al
    Clinical Significance of Clonal Hematopoiesis in the Setting of Autologous Stem Cell Transplantation for Lymphoma.
    Am J Hematol. 2022 Sep 10. doi: 10.1002/ajh.26726.
    PubMed     Abstract available

  30. ALABDALJABAR MS, Durani U, Thompson CA, Constine LS, et al
    The Forgotten Survivor: A comprehensive review on Non-Hodgkin Lymphoma Survivorship.
    Am J Hematol. 2022 Sep 7. doi: 10.1002/ajh.26719.
    PubMed     Abstract available

  31. ALDERUCCIO JP, Reis IM, Habermann TM, Link BK, et al
    Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.
    Am J Hematol. 2022 Sep 3. doi: 10.1002/ajh.26715.
    PubMed     Abstract available

  32. YING Z, Zou D, Yang H, Wu J, et al
    Preliminary Efficacy and Safety of Relmacabtagene Autoleucel (Carteyva) in Adults with Relapsed/Refractory Follicular Lymphoma in China: A Phase I/II Clinical Trial.
    Am J Hematol. 2022 Sep 1. doi: 10.1002/ajh.26711.

    August 2022
  33. ALDERUCCIO JP, Habermann T, Kuker R, Moskowitz CH, et al
    A roadmap for clinical trial design in marginal zone lymphoma.
    Am J Hematol. 2022 Aug 28. doi: 10.1002/ajh.26706.

    July 2022
  34. DU J, Wei R, Jiang S, Jiang H, et al
    CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
    Am J Hematol. 2022;97:933-941.
    PubMed     Abstract available

  35. ABUSHUKAIR H, Syaj S, Ababneh O, Qarqash A, et al
    First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenstrom's Macroglobulinemia: A systematic review and meta-analysis.
    Am J Hematol. 2022;97:942-950.
    PubMed     Abstract available

    June 2022
  36. LIM JQ, Huang D, Chan JY, Laurensia Y, et al
    A genomic-augmented multivariate prognostic model for the survival of Natural-killer/T-cell lymphoma patients from an international cohort.
    Am J Hematol. 2022 Jun 20. doi: 10.1002/ajh.26636.
    PubMed     Abstract available

  37. SEEGOBIN K, Li Z, Alhaj Moustafa M, Majeed U, et al
    Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003-2018).
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26635.
    PubMed     Abstract available

  38. JABBOUR EJ, Short NJ, Jain N, Jammal N, et al
    Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at a Threshold of 10(-4) and Higher.
    Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
    PubMed     Abstract available

    May 2022
  39. SAUL EE, Alderuccio JP, Reis IM, Zhao W, et al
    Long-term outcomes of patients with conjunctival extranodal marginal zone lymphoma.
    Am J Hematol. 2022 May 12. doi: 10.1002/ajh.26591.
    PubMed     Abstract available

  40. EVANS MG, Crymes A, Crombie JL, Basu SS, et al
    Monotypic plasmacytoid cells mimicking lymph node malignancy in the setting of COVID-19 recovery.
    Am J Hematol. 2022;97:666-667.

  41. WANG J, Zhang X, Zhou Z, Liu Y, et al
    A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2022 May 1. doi: 10.1002/ajh.26586.
    PubMed     Abstract available

    April 2022
  42. MALPICA L, Marques-Piubelli ML, Beltran BE, Chavez JC, et al
    EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification and management.
    Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26579.
    PubMed     Abstract available

  43. HOPKINS D, Smyth D, Leach M, Bain BJ, et al
    Breast implant-associated anaplastic large cell lymphoma.
    Am J Hematol. 2022 Apr 20. doi: 10.1002/ajh.26574.

  44. BANSAL R, Novo M, Al Saleh AS, Guerrico AG, et al
    Peak Absolute Lymphocyte Count After CAR-T Infusion Predicts Clinical Response in Aggressive Lymphoma.
    Am J Hematol. 2022 Apr 6. doi: 10.1002/ajh.26561.

    March 2022
  45. COOK L, Al-Yousuf H, Mohamedbhai S, Bain BJ, et al
    Hyposplenism in adult T-cell leukemia/lymphoma.
    Am J Hematol. 2022 Mar 26. doi: 10.1002/ajh.26547.

  46. OVLISEN AK, Jakobsen LH, Kragholm KH, Nielsen RE, et al
    Mental Health Among Patients with non-Hodgkin Lymphoma: a Danish Nationwide Study of Psychotropic Drug Use in 8,750Patients and 43,750 Matched Comparators.
    Am J Hematol. 2022 Mar 17. doi: 10.1002/ajh.26538.
    PubMed     Abstract available

  47. EVENS AM, Brandt JS, Peer CJ, Yin T, et al
    Checkpoint Inhibitor Immunotherapy during Pregnancy for Relapsed/Refractory Hodgkin Lymphoma.
    Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26527.

  48. JAIN P, Wang M
    Mantle cell lymphoma in 2022 - A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
    Am J Hematol. 2022 Mar 10. doi: 10.1002/ajh.26523.
    PubMed     Abstract available

  49. TA R, Hasserjian RP, Nardi V
    An Unusual Lymphoma Involving the GI Tract and Bone Marrow.
    Am J Hematol. 2022 Mar 7. doi: 10.1002/ajh.26513.

    February 2022
  50. POMMERT L, Schafer ES, Malvar J, Gossai N, et al
    Decitabine and Vorinostat with FLAG Chemotherapy in Pediatric Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
    Am J Hematol. 2022 Feb 18. doi: 10.1002/ajh.26510.
    PubMed     Abstract available

  51. YHIM HY, Eshet Y, Metser U, Lajkosz K, et al
    Risk stratification for relapsed/refractory classical Hodgkin lymphoma integrating pre-transplant Deauville score and residual metabolic tumor volume.
    Am J Hematol. 2022 Feb 16. doi: 10.1002/ajh.26500.
    PubMed     Abstract available

  52. WANG Y, Zhang M, Song W, Cai Q, et al
    Chidamide plus Prednisone, Etoposide, and Thalidomide for Untreated Angioimmunoblastic T-cell Lymphoma in a Chinese Population: A Multicenter Phase II Trial.
    Am J Hematol. 2022 Feb 15. doi: 10.1002/ajh.26499.
    PubMed     Abstract available

  53. UJJANI C, Greninger AL, Shadman M, Hill JA, et al
    Heterologous SARS-CoV-2 vaccinations in patients with B-cell lymphoid malignancies.
    Am J Hematol. 2022;97:E67-E69.

    January 2022
  54. DORFMAN DM, Pinkus GS
    A case of peripheral T-cell lymphoma, NOS mimicking acute monocytic leukemia.
    Am J Hematol. 2022 Jan 22. doi: 10.1002/ajh.26476.

  55. PHILLIPS T, Brunvand M, Chen AI, Essell J, et al
    Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non-Hodgkin lymphomas: A phase IB/II study.
    Am J Hematol. 2022;97:E24-E27.

    December 2021
  56. MOSHREF RAZAVI H, Henrie R, Hrynchak M, Minor A, et al
    Aggressive B cell lymphoma with t(3;8)(q27;q24). in an elderly patient.
    Am J Hematol. 2021 Dec 6. doi: 10.1002/ajh.26430.

    October 2021
  57. KOZAK M, Eno C, Vail E, Kitahara S, et al
    The elusive but classic presentation of small cell variant of ALK+ anaplastic large cell lymphoma (ALCL).
    Am J Hematol. 2021 Oct 29. doi: 10.1002/ajh.26394.

  58. ZHANG T, Lu Y, Liu X, Zhao M, et al
    Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B cell lymphoma.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26392.

  59. HO M, Zanwar S, Duggan P, Carr R, et al
    Hiding in (Not So) Plain Sight: Spontaneous Tumor Lysis Syndrome due to Intravascular Large B Cell Lymphoma.
    Am J Hematol. 2021 Oct 22. doi: 10.1002/ajh.26383.
    PubMed     Abstract available

  60. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    PubMed     Abstract available

  61. BARRETO JN, Bansal R, Hathcock MA, Doleski CJ, et al
    The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy.
    Am J Hematol. 2021;96:E399-E402.

  62. TINTLE S, Fuda F, Chen W
    Restricted TRBC1 expression: A clonality marker for circulating Sezary cells.
    Am J Hematol. 2021;96:1338-1339.

  63. WESTIN JR, Kersten MJ, Salles G, Abramson JS, et al
    Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.
    Am J Hematol. 2021;96:1295-1312.
    PubMed     Abstract available

  64. HRISTOV AC, Tejasvi T, A Wilcox R
    Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management.
    Am J Hematol. 2021;96:1313-1328.
    PubMed     Abstract available

  65. Abstracts from the 2021 Lymphoma and Myeloma Congress October 19-23, 2021.
    Am J Hematol. 2021;96 Suppl 1:S3-S33.

    September 2021
  66. S MEHTA R, Torres Cabala CA, DiNardo CD, Daver N, et al
    Post-transplantation donor-derived Sezary syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis.
    Am J Hematol. 2021;96:E350-E353.

    August 2021
  67. SIOW W, Matthey F, Bain BJ
    Eosinophil morphology in the reactive eosinophilia of Hodgkin lymphoma.
    Am J Hematol. 2021 Aug 30. doi: 10.1002/ajh.26337.

  68. ZHANG Y, Ma S, Cai J, Yang Y, et al
    Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: a multicenter study.
    Am J Hematol. 2021 Aug 27. doi: 10.1002/ajh.26335.
    PubMed     Abstract available

  69. WUDHIKARN K, Bansal R, Khurana A, Hathcock MA, et al
    Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.
    Am J Hematol. 2021 Aug 23. doi: 10.1002/ajh.26330.

  70. JURGENS EM, Ketas TJ, Zhao Z, Satlin MJ, et al
    Serologic response to mRNA COVID-19 vaccination in lymphoma patients.
    Am J Hematol. 2021 Aug 14. doi: 10.1002/ajh.26322.

  71. ZAIN JM, Hanona P
    Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:1027-1046.
    PubMed     Abstract available

    July 2021
  72. KARMALI R, Switchenko JM, Goyal S, Shanmugasundaram K, et al
    Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.
    Am J Hematol. 2021 Jul 29. doi: 10.1002/ajh.26306.
    PubMed     Abstract available

  73. KHURANA A, Hathcock M, Habermann TM, Al Saleh A, et al
    Lines of Therapy before Autologous Stem Cell Transplant and CAR-T Affect Outcomes in Aggressive Non-Hodgkin's Lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26293.

  74. CASTILLO JJ, Lamacchia J, Silver J, Flynn CA, et al
    Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma.
    Am J Hematol. 2021 Jul 14. doi: 10.1002/ajh.26291.

  75. MEHTA-SHAH N, Lunning MA, Moskowitz AJ, Boruchov AM, et al
    Romidepsin and lenalidomide based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts.
    Am J Hematol. 2021 Jul 12. doi: 10.1002/ajh.26288.
    PubMed     Abstract available

  76. VAUGHN JL, Spies D, Xavier AC, Epperla N, et al
    Racial disparities in the survival of patients with indolent non-Hodgkin lymphomas in the United States.
    Am J Hematol. 2021;96:816-822.
    PubMed     Abstract available

    June 2021
  77. SARKOZY C, Michot JM, Quivoron C, Camara-Clayette V, et al
    Innovative therapies based on molecular orientation in patients with Relapse and Refractory diffuse large B cell lymphoma, results of LNH-EP1 study.
    Am J Hematol. 2021 Jun 24. doi: 10.1002/ajh.26280.

  78. DEFRANCESCO I, Visentini M, Zibellini S, Minafo YA, et al
    Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders.
    Am J Hematol. 2021;96:E210-E214.

    May 2021
  79. MARTINEZ-CALLE N, Wilson MR, Eyre TA, Cwynarski K, et al
    Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in Diffuse Large B-cell Lymphoma; caution required.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26257.

  80. PUCKRIN R, Stewart DA
    Prophylactic high-dose methotrexate in diffuse large B cell lymphoma, authors' response.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26256.

  81. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.

  82. KHURANA A, Dalland J, Young JR, Inwards DJ, et al
    Brexucabtagene Autoleucel Therapy Induces Complete Remission in a Primary Refractory Blastoid Mantle Cell Lymphoma with Neurolymphomatosis.
    Am J Hematol. 2021 May 13. doi: 10.1002/ajh.26233.

  83. BODDICKER NJ, Larson MC, Castellino A, Herrmann J, et al
    Anthracycline Treatment, Cardiovascular Risk Factors and the Cumulative Incidence of Cardiovascular Disease in a Cohort of Newly Diagnosed Lymphoma Patients from the Modern Treatment Era.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26230.
    PubMed     Abstract available

    April 2021
  84. DULERY R, Lamure S, Delord M, Di Blasi R, et al
    Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.
    Am J Hematol. 2021 Apr 28. doi: 10.1002/ajh.26209.
    PubMed     Abstract available

  85. WALTER LP, Couronne L, Jais JP, Nguyen PD, et al
    Outcome after Haematopoietic Stem Cell Transplantation in Patients with Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: a French Study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26200.
    PubMed     Abstract available

  86. LAM M, Touitou V, Choquet S, Cassoux N, et al
    Intravenous high-dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an LOC network study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26199.
    PubMed     Abstract available

  87. PUCKRIN R, El Darsa H, Ghosh S, Peters A, et al
    Ineffectiveness of High-Dose Methotrexate for Prevention of CNS Relapse in Diffuse Large B Cell Lymphoma.
    Am J Hematol. 2021 Apr 3. doi: 10.1002/ajh.26181.
    PubMed     Abstract available

  88. NAGLE SJ, Murphree C, Raess PW, Schachter L, et al
    Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies.
    Am J Hematol. 2021;96:455-461.
    PubMed     Abstract available

    April 2020
  89. WANG W, Zhang Y, Zhang L, Yang C, et al
    Intravenous methotrexate at a dose of 1 g/m(2) incorporated into RCHOP prevented CNS relapse in high-risk DLBCL patients: A prospective, historic controlled study.
    Am J Hematol. 2020;95:E80-E83.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.